DPA-714 and FDG PET/MRI in Depression
ConditionDepression
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-85
SponsorThe First Affiliated Hospital of Dalian Medical University
About this trial
Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.
Eligibility criteria
Qualifiers
No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination
MMSE≥24 points，MOCA≥26 points
No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks
Patients with diabetes had fasting controlled below 9.0mmol/L before the examination
Disqualifiers
Have a history of organic mental disorders or other mental disorders
A family history of hereditary diseases
Persons with mental retardation or dementia
A history of psychoactive substance abuse
Trial design
Treatments tested in this trial
- PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG
Treatment groups
70 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov